Biotech Business - February 13, 2023
Akiram Therapeutics raises 68 million SEK
The DDD Platform spin-out company has secured investments from Sciety Venture Partners and Linc AB, in a venture capital round led by Sciety. The investment company Linc AB participated in the share issue with SEK 20 million. “We would like to thank Sciety and all those who have participated in this successful issue for the […]
Biotech Business - February 7, 2023
TILT Biotherapeutics closes 22 million EUR financing round
The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. This follows on from the first close of 10 million EUR in June 2022. This final close of 12 million EUR includes 5.9 million EUR equity from the European Innovation Council (EIC) Fund as well as a 2.1 […]
Biotech Business - January 30, 2023
AdjuTec Pharma attracts public funding to optimize manufacturing
Just before Christmas, the Norwegian company announced that it has received support from Oslo County of 1.950 million NOK. The funding will support optimization of the synthesis of our two lead compounds, APC148 and APC247. The program will define the optimal characteristics of the substances that will be used for microbiology testing as well as […]
Financing - January 25, 2023
AI Medical Technology nets 10.8 million SEK
The startup company has completed a heavily oversubscribed fundraise. The new funds will be used initially to expand the company’s clinical trial program for its Dermalyser AI-driven support tool in Sweden and other key European markets, as well as finalize CE marking and commercialization, states the company. In addition, the company is starting to work towards […]
Financing - January 19, 2023
Sigrid Therapeutics raises 10.6 million SEK
The company has raised an additional 10.6 million SEK to accelerate commercialization of its SiPore health and food supplement portfolio. “In the current climate, the rapid completion and oversubscription of this new fund raise is a sign of confidence in both SiPor’s huge potential and our commercialization strategy. In addition to our core prediabetes market, we […]
Biotech Business - January 18, 2023
BioInvent selected to the Leukemia & Lymphoma Society’s Therapy Acceleration Program
The partnership will include access to the scientific, clinical and drug development expertise of the Leukemia & Lymphoma Society (LLS) as well as a strategic capital equity investment from LLS TAP of 3 million USD. The acceleration program aims to advance the BioInvent International’s program to treat blood cancers, states the company in a press […]
